July 22nd 2024
A clinician outlines their treatment strategy for relapsed/refractory chronic lymphocytic leukemia patients, emphasizing how previous treatment history influences subsequent therapy choices.
An expert in the field provides insights into current clinical trials investigating the efficacy of combined BCL-2 inhibitor and BTK inhibitor therapies.
July 16th 2024
John N. Allan, MD, provides clinical insights on how appropriate dose ramp-up practices for venetoclax can minimize adverse events and optimize patient outcomes.
Bita Fakhri, MD, MPH, discusses the importance of patient involvement in the shared decision-making process to individualize treatment and improve outcomes.
July 15th 2024
Experts analyze the potential applications of triplet therapy (venetoclax, BTK inhibitor, and obinutuzumab) in first-line chronic lymphocytic leukemia treatment, focusing on patient subgroups most likely to benefit from this approach.
A chronic lymphocytic leukemia expert examines patient criteria for first-line doublet therapy (venetoclax plus BTK inhibitor) versus triplet therapy, while also addressing findings from the CAPTIVATE trial.
July 9th 2024
Experts on chronic lymphocytic leukemia detail how clinical trial data on doublet therapies help inform treatment decisions in the first line.
Focusing on the CLL13 and CLL14 studies, Bita Fakhri, MD, MPH, provides insights on the role of venetoclax-based first-line combination strategies and factors that inform treatment selection.
July 8th 2024
The panelists explore strategies for managing front-line chronic lymphocytic leukemia (CLL) treatment in patients with pre-existing hypertension and atrial fibrillation.
Key opinion leaders examine the use of continuous Bruton's tyrosine kinase inhibitor therapy in front-line treatment, strategies for sequencing therapies, and the potential incorporation of obinutuzumab into treatment regimens.
July 3rd 2024
Catherine C. Coombs, MD, discusses the value of real-world data in informing the treatment of patients with chronic lymphocytic leukemia.
John N. Allan, MD, describes how he selects patients for first-line treatment with continuous BTK inhibitor therapy, referencing data from the RESONATE-2, ELEVATE-TN, and SEQUOIA studies.
June 27th 2024
Leading chronic lymphocytic leukemia specialists explore strategies for selecting initial treatments, weighing the merits of fixed-duration versus continuous Bruton's tyrosine kinase inhibitor (BTKi) therapy for newly diagnosed patients.
Key opinion leaders are introduced and present a concise overview of the topics to be addressed.
June 25th 2024
Bita Fakhri, MD, MPH, outlines factors she considers when choosing between fixed-duration and continuous BTK inhibitor therapy and discusses how she approaches treatment discussions with patients.
A panel of experts on chronic lymphocytic leukemia (CLL) review a patient case and describe their initial impressions on treatment decisions.
April 22nd 2024
Catherine C. Coombs, MD, discusses the efficacy of the FLT3 inhibitor quizartinib in acute myeloid leukemia.
April 18th 2024
Catherine C. Coombs, MD, discusses strategies for disease classification and management for patients with acute myeloid leukemia.
April 5th 2024
Catherine C. Coombs, MD, discusses the mechanism of action of noncovalent BTK inhibitors in patients with relapsed/refractory mantle cell lymphoma.
February 16th 2024
A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.